J. Vansteenkiste discuss how to decide among available therapies for advanced NSCLC in a time of rapidly evolved advances in targeted and immunotherapy, and biomarkers development. He elaborates the results from CheckMate 063 with nivolumab in refractory squamous NSCLC, as presented at ELCC 2016 and exploratory cytokine profiling analyses.

Oncology Meeting Resources

Major Sponsors

AstraZeneca Janssen

Main Sponsors

Amgen Astellas Bayer Healthcare Boehringer Ingelheim Daiichi Sankyo Genomic Health Inc. Lilly Oncology Roche